5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.2%) at 12,810 as of Wednesday, Nov. 21, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,635 issues advancing vs. 1,204 declining with 167 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is up 0.0%. On the negative front, top decliners within the sector include DaVita HealthCare Partners ( DVA), down 1.8%, Edwards Life ( EW), down 1.3%, Humana ( HUM), down 1.0%, Sanofi ( SNY), down 0.6% and Express Scripts ( ESRX), down 0.7%. Top gainers within the sector include Thoratec Corporation ( THOR), up 4.9%, Boston Scientific ( BSX), up 3.2%, Shire ( SHPG), up 1.5% and Becton Dickinson ( BDX), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Vertex Pharmaceuticals is down $1.10 (-2.6%) to $41.06 on light volume Thus far, 615,588 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $40.69-$42.15 after having opened the day at $42.11 as compared to the previous trading day's close of $42.16.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $9.0 billion and is part of the drugs industry. The company has a P/E ratio of 66.8, above the S&P 500 P/E ratio of 17.7. Shares are up 24.8% year to date as of the close of trading on Tuesday. Currently there are 15 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

4. As of noon trading, St Jude Medical ( STJ) is down $4.36 (-12.2%) to $31.35 on heavy volume Thus far, 11.6 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $31.24-$34.00 after having opened the day at $33.75 as compared to the previous trading day's close of $35.71.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. St Jude Medical has a market cap of $11.0 billion and is part of the health services industry. The company has a P/E ratio of 15.0, below the S&P 500 P/E ratio of 17.7. Shares are up 4.2% year to date as of the close of trading on Tuesday. Currently there are 15 analysts that rate St Jude Medical a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full St Jude Medical Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

3. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.75 (-1.2%) to $61.08 on light volume Thus far, 674,127 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $61.05-$61.72 after having opened the day at $61.69 as compared to the previous trading day's close of $61.83.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $22.1 billion and is part of the health services industry. The company has a P/E ratio of 19.6, above the S&P 500 P/E ratio of 17.7. Shares are up 36.6% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Thermo Fisher Scientific Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

2. As of noon trading, Covidien ( COV) is down $0.43 (-0.8%) to $56.41 on light volume Thus far, 583,191 shares of Covidien exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $56.27-$56.78 after having opened the day at $56.78 as compared to the previous trading day's close of $56.84.

Covidien Public Limited Company develops, manufactures, and sells healthcare products for use in clinical and home settings in the United States and internationally. Covidien has a market cap of $26.9 billion and is part of the health services industry. The company has a P/E ratio of 14.5, below the S&P 500 P/E ratio of 17.7. Shares are up 26.1% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Covidien a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Covidien Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

1. As of noon trading, Gilead ( GILD) is down $0.68 (-0.9%) to $75.13 on light volume Thus far, 1.8 million shares of Gilead exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $74.78-$75.99 after having opened the day at $75.74 as compared to the previous trading day's close of $75.81.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $56.7 billion and is part of the drugs industry. The company has a P/E ratio of 23.2, above the S&P 500 P/E ratio of 17.7. Shares are up 82.8% year to date as of the close of trading on Tuesday. Currently there are 20 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Gilead Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday